EDTA Tube

EDTA Tube

EDTA tubes are purple cap test tubes whose inner walls are coated with spray-dried EDTA. EDTA acts as an anticoagulant that binds the calcium ions and in the process interrupts the clotting of blood samples. EDTA tubes have a wide range of applications as they are used for majority of the hematology procedures such as assessing complete blood count, preparing EDTA plasma, whole blood collections, and bone marrow specimens. These tubes are a very essential part of the healthcare and diagnostic industry, where they are used for collecting blood samples, storage of those samples, as well as keeps them safe and protected from the environment. Furthermore, they serve as a valuable specimen in the research and development industry.

The EDTA Tubes market is expected to grow at a strong CAGR of around 7.5% during the forecast period owing to the increasing interest of people in preventive diagnostics. Furthermore, higher life expectancy and an aging population where 55-60% of the population is expected to be above 45 years of age in the coming census are boosting the demand for EDTA tubes in the healthcare and diagnostics industry. For instance, According to World Population Prospects 2019 (United Nations, 2019), by 2050, 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019. Moreover, the increasing health consciousness and disposable incomes of the populace and improved customer convenience with increasing home testing and specialized test menu are further contributing to the growth of the EDTA market with the growing diagnostic industry due to an increase in conditions like prediabetes, high cholesterol levels, etc due to modern-day sedentary lifestyle. For instance, in October 2019, as per national diabetes statistics report, 37.3 million people of all ages had diabetes (11.3% of the population) in 2019. 37.1 million were adults ages 18 years or older, where 28.7 million people of all ages had been diagnosed with diabetes (8.7% of the population), and 8.5 million adults ages 18 years or older had diabetes but were undiagnosed (23% of adults with diabetes were undiagnosed), where the total estimated cost of diagnosed diabetes in 2017 was USD 327 billion, including USD 237 billion in direct medical costs and USD 90 billion in reduced productivity.

• Based on additives used, the market is bifurcated into K2 EDTA and K3 EDTA. The K2 EDTA is anticipated to witness significant CAGR during the forecast period owing to the fact that K2 EDTA is preferred over K3 EDTA because it is more hypertonic and causes erythrocyte dehydration and shrinkage. Furthermore, another drawback of K3 EDTA is it is a liquid anticoagulant that results in the dilution of the blood specimen, which lowers most of the measurement including RBC, WBC, platelet, MCV, and hemoglobin.
• Based on capacity, the market is segmented into <2ml, 2ml-4ml, 6ml, and >6ml. The >6ml size EDTA tubes holds the significant share of the market. The primary reason for this domination is, blood tests are the most common medical tests across the globe with hematocrit being the most common type of test and EDTA tubes are used for these, and almost 30 ml of blood is required for these checkups making the >6ml vial segment the most preffered one. The major reasons because of which blood tests are on the rise are regular physical checkup with increased awareness and health consciousness, screening tests are also on the rise if the person is at the verge of developing certain conditions. Moreover, rising health conditions in all age groups due to sedentary lifestyles and severe environmental conditions such as pollution is also boosting the demand for blood tests. For instance, as per the report published by the World Health Organization (WHO) in December 2022, air pollution is one of the greatest environmental risks to health. By reducing air pollution levels, countries can reduce the burden of disease from stroke, heart disease, lung cancer, and both chronic and acute respiratory diseases, including asthma. Ambient (outdoor) air pollution is estimated to have caused 4.2 million premature deaths worldwide in 2019, where some 89% of those premature deaths occurred in low- and middle-income countries and the greatest number in the WHO South-East Asia and Western Pacific Regions.
• Based on application, the market is segmented into complete blood count (CBC), blood smear, coagulation tests, bone marrow biopsy, and others. The CBC segment holds the majority of the market share. The primary reason for CBC tests to be the most common type of blood test are, CBC is the first most test that is prescribed to almost every patient at the start of their treatment. Furthermore, CBC tests help doctors evaluate the overall health of the patient, it is also done to detect any sort of disorder in the patient such as leukemia or anemia, which is often caused due to lower blood cell count. Moreover, CBC tests are done to give an overall report of the patient’s health, to help diagnose medical conditions, and to monitor how medical treatment is working. And with the rising population, increased health consciousness among the populace, and improving healthcare infrastructure and awareness among the population along with increasing health conditions due to modern lifestyle are some of the factors that will contribute to the growth of this segment for the forecasted period.
• Based on end-user industry the market is segmented into hospitals, diagnostic centers, R&D centers, and others. The diagnostic industry is anticipated to witness a significant CAGR growth during the forecasted period. The notable reasons that will primarily drive this growth are changing demographics, increasing lifestyle diseases, and higher income levels across all strata of society has led to a rise in preventive testing with increased health awareness. Furthermore, the diagnostic industry is adopting a very scalable model which has helped in the rapid expansion of this industry where they are deepening their penetration with the asset-light model, increasing their ability to perform complex tests, developing hub and spoke logistics model, as well strengthening their IT infrastructure and centralizing their operations.
• For a better understanding of the market adoption of EDTA tubes, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, Rest of Asia-Pacific), Rest of World. The EDTA tube market in the Asia Pacific is expected to witness significant CAGR growth during the forecast period. The primary factors driving this growth are the rising population with an equally rising aging population who requires more frequent medical attention. Furthermore, with the rising income levels of the populace in these regions, people are upgrading their lifestyles which has increased health consciousness and awareness has given a surge to the demand for preventive care and wellness which is further stimulated by COVID-19. Moreover, with spreading healthcare services, expanding healthcare infrastructure, and rising insurance penetration are also contributing to the growth of this industry. Additionally, there has been an increase in the reporting of chronic and lifestyle diseases due to sedentary lifestyle, and bad environmental and pollution conditions in these emerging economies have led to an increase in medical conditions among a large portion of the population and especially in urban regions where affordability is not an issue, and driving up the demand for the medical services which in turn is boosting the demand for the EDTA tubes in these regions. For instance, in February 2023, as per the Department of Biotechnology, India, Chronic or Non-communicable diseases are on the rise across the globe accounting for 73% of all deaths. In India, non-communicable diseases account for 53% of all deaths and 44 % of disability-adjusted life-years lost. India has the highest number of people with Diabetes in the world with around 77 million living with diabetes and a projection of 134 million by 2045 (International Diabetes Federation). India suffers loss of life at an early age due to cardiovascular disease which accounts for one-fourth of all deaths.
• Some of the major players operating in the market include Vitrex Medical; HWTAI; VACUTEST KIMA S.r.l; Disera Tıbbi Malzeme Lojistik Sanayi ve Ticaret A.Ş; WEGO Medical International Trade Co., Ltd.; Advin Health Care; Apex Bio Medicals; Proexamine Surgicals Pvt. Ltd.; Medis Medical; and VWR International, LLC.